Browsing by Author "Rondon, C"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Effectiveness of montelukast in pediatric patients with allergic rhinitis
    Yilmaz, O; Altintas, D; Rondon, C; Cingi, C; Oghan, F
    Allergic rhinitis (AR) is one of the most common chronic diseases of childhood and carries significant morbidity as well as physical and psychosocial consequences. Therapy aims to alleviate clinical symptoms, prevent complications and improve psychosocial consequences. Leukotrienes which are amongst the main mediators in pathogenesis of AR have chemotactic properties and lead to increased vascular permeability. Thus, leukotriene antagonism may be an effective therapeutic option in treatment of allergic diseases, specifically AR. Montelukast which is a leukotriene receptor type I inhibitor has variable efficacy in children with AR and the guidelines recommend its use in children with seasonal AR aged six years and above. Although its efficacy is inferior to anti-histamines and intranasal corticosteroids, combination treatment may warrant clinical efficacy. Therefore, montelukast may be considered to be a well-tolerated therapeutic option for children with AR with minor side effects though long term results need to be assessed. In conclusion, larger scale research enrolling pediatric cases with seasonal and persistent AR are required before concise recommendations about montelukast use in pediatric AR can be made. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Management of anaphylaxis due to COVID-19 vaccines in the elderly
    Bousquet, J; Agache, I; Blain, H; Jutel, M; Ventura, MT; Worm, M; Del Giacco, S; Benetos, A; Bilo, BM; Czarlewski, W; Latiff, AHA; Al-Ahmad, M; Angier, E; Annesi-Maesano, I; Atanaskovic-Markovic, M; Bachert, C; Barbaud, A; Bedbrook, A; Bennoor, KS; Berghea, EC; Bindslev-Jensen, C; Bonini, S; Bosnic-Anticevich, S; Brockow, K; Brussino, L; Camargos, P; Canonica, GW; Cardona, V; Carreiro-Martins, P; Carriazo, A; Casale, T; Caubet, JC; Cecchi, L; Cherubini, A; Christoff, G; Chu, DRK; Cruz, AA; Dokic, D; El-Gamal, Y; Ebisawa, M; Eberlein, B; Farrell, J; Fernandez-Rivas, M; Fokkens, WJ; Fonseca, JA; Gao, YD; Gavazzi, G; Gawlik, R; Gelincik, A; Gemicioglu, B; Gotua, M; Guérin, O; Haahtela, T; Hoffmann-Sommergruber, K; Hoffmann, HJ; Hofmann, M; Hrubisko, M; Illario, M; Irani, C; Ispayeva, Z; Ivancevich, JC; Julge, K; Kaidashev, I; Khaitov, M; Knol, E; Kraxner, H; Kuna, P; Kvedariene, V; Lauerma, A; Le, LTT; Le Moing, V; Levin, M; Louis, R; Lourenco, O; Mahler, V; Martin, FC; Matucci, A; Milenkovic, B; Miot, S; Montella, E; Morais-Almeida, M; Mortz, CG; Mullol, J; Namazova-Baranova, L; Neffen, H; Nekam, K; Niedoszytko, M; Odemyr, M; O'Hehir, RE; Okamoto, Y; Ollert, M; Palomares, O; Papadopoulos, NG; Panzner, P; Passalacqua, G; Patella, V; Petrovic, M; Pfaar, O; Pham-Thi, N; Plavec, D; Popov, TA; Recto, MT; Regateiro, FS; Reynes, J; Roller-Winsberger, RE; Rolland, Y; Romano, A; Rondon, C; Rottem, M; Rouadi, PW; Salles, N; Samolinski, B; Santos, AF; Sarquis, FS; Sastre, J; Schols, JMGA; Scichilone, N; Sediva, A; Shamji, MH; Sheikh, A; Skypala, I; Smolinska, S; Sokolowska, M; Sousa-Pinto, B; Sova, M; Stelmach, R; Sturm, G; Ulrik, CS; Todo-Bom, AM; Toppila-Salmi, S; Tsiligianni, I; Torres, M; Untersmayr, E; Pereira, MU; Valiulis, A; Vitte, J; Vultaggio, A; Wallace, D; Walusiak-Skorupa, J; Wang, DY; Waserman, S; Yorgancioglu, A; Yusuf, OM; Zernotti, M; Zidarn, M; Chivato, T; Akdis, CA; Zuberbier, T; Klimek, L
    Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients.